TG Therapeutics TGTX EBITDA

EBITDA at other companies

Rhythm Pharmaceuticals, Inc.RYTM

-$43.93M-28.8%

Mirum Pharmaceuticals, Inc.MIRM

-$35.6M-3,437%

Vor BiopharmaVOR

-$35.13M-8.2%

Ultragenyx PharmaceuticalRARE

-$67M+32.3%

Shattuck Labs, Inc.STTK

-$14.65M-8.9%

BridgeBio PharmaBBIO

——

FAQ

What is TG Therapeutics's EBITDA?

TG Therapeutics (TGTX) reported EBITDA of $21.73M in Q2 2026.

How has TG Therapeutics's EBITDA changed year-over-year?

TG Therapeutics's EBITDA decreased by 37.7% year-over-year, from $34.86M to $21.73M.

What is the long-term trend for TG Therapeutics's EBITDA?

Over 3 years (2021 to 2025), TG Therapeutics's EBITDA has grown at a -29.0% compound annual growth rate (CAGR), from -$344.49M to $123.38M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.